2D ago
Trending
23 sources
Treat 'abundance' not only as a macro industrial policy but as a targeted small‑business strategy: reduce permitting and compliance overhead, accelerate infrastructure in struggling towns, and pair that with demand‑side measures (transmission, zoning for industry) so new customers arrive. The synthesis reframes abundance as both supply‑side (lower regulatory fixed costs) and demand‑side (infrastructure‑enabled population/employment growth) policy for local revitalization.
— If framed this way, 'abundance' becomes politically relevant to mayors and councilors seeking tangible small‑business wins rather than an abstract tech‑industrial slogan.
Sources: At least five interesting things: Buy Local edition (#74), Thursday assorted links, There has to be a better way to make titanium (+20 more)
21D ago
Trending
22 sources
Public lists or 'blueprints' of candidate alleles (shared by prominent scientists) can act as operational playbooks that lower the barrier for embryo selection, private editing, or third‑party analytics to produce enhancements. Making such lists public shifts the problem from speculative ethics to near‑term governance: who can access, implement, or monetize these targets and what safety/consent rules apply.
— If blueprints circulate, policymakers must rapidly address regulation, equitable access, and biosecurity to prevent privatized enhancement arms races and entrenched genetic inequality.
Sources: A Boomer Geneticist's Approach to Human Enhancement, PALLADIUM 18: Biological Inheritance - by Palladium Editors, Protective alleles (+19 more)
28D ago
Trending
7 sources
Mainstream cultural outlets are beginning to advertise the normalization of human‑altering biotechnologies (embryo selection, artificial wombs, organ farming) and call for public debate; this suggests the next phase will be contest over governance, distribution, and legal status rather than purely scientific questions. A coordinated set of transparency, licensing, and equity rules—designed in public and across jurisdictions—will be necessary to prevent private capture and social stratification.
— Framing these technologies as a governance problem (not just a science one) focuses public discourse on who decides, who benefits, and which institutions must be reformed to manage biological inheritance.
Sources: PALLADIUM 18: Biological Inheritance - by Palladium Editors, These Bacteria Beat Cancer By Eating Cancer, Is This Where Morality Lives in the Brain? (+4 more)
28D ago
1 sources
CRISPR‑era editing cuts development time and cost enough that treatments for very small patient populations — previously 'too small' to commercialize — become viable. That shifts pharma economics, testing pathways, and who gets prioritized for scarce regulatory attention.
— If genome editing makes rare‑disease drugs commercially viable, policymakers and payers will face new questions about pricing, equitable access, and accelerated approval norms.
Sources: What genome editing tech has done for the world, so far
6M ago
1 sources
Scientists and startups are developing systems that use solar energy and engineered microbes or electrochemical processes to produce edible biomass without growing conventional crops or raising animals. This approach replaces photosynthetic plants as the intermediary step and aims to produce protein, fats, and calories using much less land and water.
— If viable at scale, sunlight‑to‑food tech would reshape agriculture, land use, supply chains, rural labor, and climate policy by decoupling calories from farmland.
Sources: Everything you eat is sunlight. Scientists want to cut out the middleman.